572 related articles for article (PubMed ID: 29852973)
41. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
de Germay S; Pambrun E; Pariente A; Grenet G; Bezin J; Faillie JL
Diabetes Obes Metab; 2024 May; 26(5):1678-1686. PubMed ID: 38288619
[TBL] [Abstract][Full Text] [Related]
42. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies.
Li CX; Liu TT; Zhang Q; Xie Q; Geng XH; Man CX; Li JY; Mao XY; Qiao Y; Liu H
Front Pharmacol; 2023; 14():1275060. PubMed ID: 37905204
[No Abstract] [Full Text] [Related]
43. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
44. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
[TBL] [Abstract][Full Text] [Related]
45. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
Papademetriou V; Geladari E
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
[TBL] [Abstract][Full Text] [Related]
46. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.
Giaccari A; Pontremoli R; Perrone Filardi P
Int J Cardiol; 2022 Mar; 351():66-70. PubMed ID: 34979145
[TBL] [Abstract][Full Text] [Related]
47. Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review.
Panico C; Bonora B; Camera A; Chilelli NC; Prato GD; Favacchio G; Grancini V; Resi V; Rondinelli M; Zarra E; Pintaudi B
Cardiovasc Diabetol; 2023 Jun; 22(1):164. PubMed ID: 37391739
[TBL] [Abstract][Full Text] [Related]
48. Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
Deerochanawong C; Chan SP; Matawaran BJ; Sheu WH; Chan J; Man NH; Suastika K; Khoo CM; Yoon KH; Luk A; Mithal A; Linong J
Diabetes Obes Metab; 2019 Nov; 21(11):2354-2367. PubMed ID: 31264765
[TBL] [Abstract][Full Text] [Related]
49. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.
Zhuo M; Li J; Buckley LF; Tummalapalli SL; Mount DB; Steele DJR; Lucier DJ; Mendu ML
Kidney360; 2022 Mar; 3(3):455-464. PubMed ID: 35582176
[TBL] [Abstract][Full Text] [Related]
50. Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis.
Duo Y; Gao J; Yuan T; Zhao W
J Diabetes; 2023 Jan; 15(1):58-70. PubMed ID: 36610036
[TBL] [Abstract][Full Text] [Related]
51. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
[TBL] [Abstract][Full Text] [Related]
52. Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care.
Hinton W; Feher M; Munro N; Joy M; de Lusignan S
Diabet Med; 2020 Sep; 37(9):1499-1508. PubMed ID: 32128875
[TBL] [Abstract][Full Text] [Related]
53. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
Permana H; Audi Yanto T; Ivan Hariyanto T
Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
[TBL] [Abstract][Full Text] [Related]
54. Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus.
Griffin TP; Islam MN; Blake L; Bell M; Griffin MD; O'Shea PM
Horm Metab Res; 2019 Feb; 51(2):91-99. PubMed ID: 30522145
[TBL] [Abstract][Full Text] [Related]
55. The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review.
Giri Ravindran S; Kakarla M; Ausaja Gambo M; Yousri Salama M; Haidar Ismail N; Tavalla P; Uppal P; Mohammed SA; Rajashekar S; Hamid P
Cureus; 2022 May; 14(5):e25476. PubMed ID: 35800782
[TBL] [Abstract][Full Text] [Related]
56. Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review.
Georgiou P; Shi W; Serhiyenia T; Akram A; Proute MC; Pradeep R; Kerolos ME; Khan S
Cureus; 2021 Oct; 13(10):e18485. PubMed ID: 34754647
[TBL] [Abstract][Full Text] [Related]
57. Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis.
Chen X; Wang L; Li H; Huang W; Huang S; Zhao L; Guo W
Front Cardiovasc Med; 2022; 9():1067806. PubMed ID: 36531703
[TBL] [Abstract][Full Text] [Related]
58. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
Singh AK; Singh R; Misra A
J Diabetes; 2021 Jul; 13(7):596-600. PubMed ID: 33792199
[TBL] [Abstract][Full Text] [Related]
59. Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials.
Ghosal S; Sinha B
Curr Diabetes Rev; 2020; 16(9):917-921. PubMed ID: 32026781
[TBL] [Abstract][Full Text] [Related]
60. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
Kasperova BJ; Mraz M; Svoboda P; Hlavacek D; Kratochvilova H; Modos I; Vrzackova N; Ivak P; Janovska P; Kobets T; Mahrik J; Riecan M; Steiner Mrazova L; Stranecky V; Netuka I; Cajka T; Kuda O; Melenovsky V; Stemberkova Hubackova S; Haluzik M
Cardiovasc Diabetol; 2024 Jun; 23(1):223. PubMed ID: 38943140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
